Status:

UNKNOWN

Quantiative MRI and Myelin-PET for the Assessment of Degenerative Cervical Myelopathy

Lead Sponsor:

Cambridge University Hospitals NHS Foundation Trust

Collaborating Sponsors:

National Institute for Health Research, United Kingdom

Wolfson Brain Imaging Centre

Conditions:

Cervical Spondylosis With Myelopathy

Degenerative Cervical Myelopathy

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

To use advanced imaging techniques, including MRI Brain and Spinal Cord, and MRI/PET Spinal Cord to provide an assessment of Degenerative Cervical Myelopathy to improve understanding of the pathophysi...

Detailed Description

Degenerative Cervical Myelopathy (DCM) is a disabling condition affecting up to 2% of adults. It arises when arthritic changes in the cervical spine compress and injure the spinal cord, causing progre...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Participant has a diagnosis of DCM, based on a combination of symptoms, signs and conventional MRI findings (Table 2)
  • Participant is scheduled for surgical treatment for DCM
  • Participant is willing and able to give informed consent for participation in the study;
  • Male or Female, aged 18 - 85 years (inclusive);
  • Exclusion Criteria
  • The participant may not enter the study if ANY of the following apply:
  • Participant unable to give informed consent;
  • Participant unable to undergo, or intolerant of MR or PET/MR imaging
  • Participant has co-existing or prior neurological disease of the brain, spinal cord, or peripheral nervous system, including but not limited to, Lumbar Canal Stenosis, Multiple Sclerosis, Dementia and Parkinson's Disease.
  • Contraindications to MRI: These are chiefly the presence of metallic implants that are not known to be MR safe, particularly in terms of movement or substantial heating. Devices that may need to be considered in this context include (this is not an exhaustive list, and this issue will be considered on a case-by-case basis for any implant or external fixation device):
  • Cerebral aneurysm clips not known to be MR safe
  • Intra-ocular metallic shards
  • Cochlear implants
  • Automatic cardioverter defibrillators
  • Nerve stimulation units
  • Other electronic implants, such as cardiac pacemakers
  • Orthopedic external fixations
  • Exclusion Criteria Specific for PET/MR Imaging Stream
  • In addition, the following exclusion criteria will apply for PET imaging, to reduce implications of exposure to ionising radiation, or interpretation of findings.
  • Female patients who are pregnant or breast-feeding
  • Participants whose DCM surgery will include the insertion of metallic implants to secure multiple levels of the spine (technically termed 'instrumentation')
  • Age \<40
  • 3.2 Volunteers
  • Inclusion Criteria
  • Participant is willing and able to give informed consent for participation in the study;
  • Male or Female, aged 18 - 85 years (inclusive); Exclusion Criteria
  • The participant may not enter the study if ANY of the following apply:
  • Participant unable to give informed consent;
  • Participant unable to undergo, or intolerant of MR imaging
  • Participant has co-existing or prior neurological disease of the brain, spinal cord, or peripheral nervous system, including but not limited to, Lumbar Canal Stenosis, Multiple Sclerosis, Dementia and Parkinson's Disease.

Exclusion

    Key Trial Info

    Start Date :

    April 17 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 1 2025

    Estimated Enrollment :

    100 Patients enrolled

    Trial Details

    Trial ID

    NCT05242666

    Start Date

    April 17 2021

    End Date

    February 1 2025

    Last Update

    May 27 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Cambridge University Hospital

    Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ